Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cocrystal Pharma ( (COCP) ) has provided an update.
On March 10, 2026, Cocrystal Pharma, Inc. announced the passing of board member Dr. Anthony Japour, marking a significant loss for the company’s leadership. His death removes an experienced figure from the board, creating a gap in governance and strategic guidance that the company will need to address as it continues its pharmaceutical development efforts.
The most recent analyst rating on (COCP) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, shrinking equity base). Technicals also remain bearish with the stock below major moving averages, while positive corporate milestones (trial initiation steps, NIH funding, and insider financing) provide partial offset but do not fully mitigate the fundamental funding and execution risks.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a biotechnology company operating in the pharmaceutical industry, focusing on the discovery and development of antiviral therapeutics. The company targets infectious diseases with unmet medical needs, aiming to advance novel small-molecule drugs through clinical development to address global health challenges.
Average Trading Volume: 71,127
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.92M
For a thorough assessment of COCP stock, go to TipRanks’ Stock Analysis page.